Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAIS Mites Sublingual Tablets
- Development stage
- Phase 2
- Lead developer
- Lofarma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Administration
- Sublingual
01
Overview
LAIS Mites Sublingual Tablets is a sublingual allergen immunotherapy (SLIT) product developed by Lofarma S.p.A. for the treatment of house dust mite (HDM) induced allergic conditions, including allergic rhinitis, conjunctivitis, and controlled asthma. The active ingredient consists of a 50/50 mixture of monomeric allergoids derived from the mite species *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. These allergoids are produced through a carbamylation process that chemically modifies the allergen's lysine residues, reducing its IgE-binding capacity (and thus the risk of systemic allergic reactions) while preserving the ability to induce T-cell tolerance and the production of protective IgG4 antibodies. The product is formulated as a once-daily sublingual tablet with a maintenance dose of 300IR (Index of Reactivity).
- Brand names
- LAISLAIS Mites
- Other names
- LAIS Mites Sublingual TabletsLofarma house dust mite SLIT tabletmonomeric allergoid house dust mite sublingual immunotherapy
02
Targets
House dust mite allergen-specific T-cell receptorHDM-specific IgE (House dust mite-specific immunoglobulin E)
Beyond the preview
Go deeper on LAIS Mites Sublingual Tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LAIS Mites Sublingual Tablets.